Bulletin
Investor Alert

New York Markets Open in:

GW Pharmaceuticals PLC ADR

NAS: GWPH

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Mar 2, 2021, 6:15 p.m.

/zigman2/quotes/209686240/composite

$

214.75

Change

-0.14 -0.07%

Volume

Volume 328

Quotes are delayed by 20 min

/zigman2/quotes/209686240/composite

Previous close

$ 214.91

$ 214.89

Change

-0.02 -0.0093%

Day low

Day high

$214.71

$215.22

Open

52 week low

52 week high

$67.98

$217.50

Open

Company Description

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures asso...

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.

Valuation

Price to Sales Ratio

6.80

Price to Book Ratio

4.87

Enterprise Value to EBITDA

-67.12

Enterprise Value to Sales

5.06

Total Debt to Enterprise Value

0.01

Efficiency

Receivables Turnover

8.85

Total Asset Turnover

0.58

Liquidity

Current Ratio

4.57

Quick Ratio

3.76

Cash Ratio

3.05

Profitability

Gross Margin

92.88

Operating Margin

-9.82

Pretax Margin

-10.44

Net Margin

-11.03

Return on Assets

-6.43

Return on Equity

-7.99

Return on Total Capital

-6.83

Return on Invested Capital

-7.70

Capital Structure

Total Debt to Total Equity

3.72

Total Debt to Total Capital

3.59

Total Debt to Total Assets

2.94

Long-Term Debt to Equity

3.72

Long-Term Debt to Total Capital

3.59

Officers and Executives

Name Age Officer Since Title
Dr. Geoffrey William Guy 65 1998 Chairman
Mr. Justin D. Gover 48 1999 Chief Executive Officer
Mr. Christopher John Tovey 54 2012 Chief Operating Officer
Mr. Scott M. Giacobello 50 2017 CFO & Principal Accounting Officer
Dr. Volker Knappertz 54 2017 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/22/2021 Adam David George
Secretary
14,700   Disposition at $11.69 per share. 171,843
01/22/2021 Adam David George
Secretary
14,700   Derivative/Non-derivative trans. at $9.61 per share. 141,267
01/21/2021 Adam David George
Secretary
1,200   Disposition at $11.76 per share. 14,112
01/21/2021 Adam David George
Secretary
23,388   Disposition at $11.69 per share. 273,405
01/21/2021 Adam David George
Secretary
24,588   Derivative/Non-derivative trans. at $9.61 per share. 236,290
01/19/2021 Adam David George
Secretary
9,600   Disposition at $11.68 per share. 112,128
01/19/2021 Volker Knappertz
Chief Medical Officer
6,000   Disposition at $11.67 per share. 70,020
01/19/2021 Adam David George
Secretary
9,600   Derivative/Non-derivative trans. at $9.61 per share. 92,256
01/15/2021 Adam David George
Secretary
26,484   Disposition at $11.75 per share. 311,187
01/15/2021 Adam David George
Secretary
53,376   Disposition at $11.72 per share. 625,566
01/15/2021 Adam David George
Secretary
1,584   Derivative/Non-derivative trans. at $9.61 per share. 15,222
01/15/2021 Adam David George
Secretary
52,560   Derivative/Non-derivative trans. at $9.81 per share. 515,613
01/15/2021 Adam David George
Secretary
25,716   Derivative/Non-derivative trans. at $10.61 per share. 272,846
01/13/2021 Adam David George
Secretary
4,740   Disposition at $11.23 per share. 53,230
01/13/2021 Adam David George
Secretary
121,764   Disposition at $11.15 per share. 1,357,668
01/13/2021 Adam David George
Secretary
222,552   Disposition at $11.08 per share. 2,465,876
01/13/2021 Adam David George
Secretary
145,200   Disposition at $11 per share. 1,597,200
01/13/2021 Adam David George
Secretary
181,488   Disposition at $10.91 per share. 1,980,034
01/13/2021 Adam David George
Secretary
77,088   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Adam David George
Secretary
96,336   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Adam David George
Secretary
5,868   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Adam David George
Secretary
5,868   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Adam David George
Secretary
5,868   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Adam David George
Secretary
5,868   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Adam David George
Secretary
78,336   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Adam David George
Secretary
132,984   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Adam David George
Secretary
99,180   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Adam David George
Secretary
67,704   Derivative/Non-derivative trans. at $3.72 per share. 251,858
01/13/2021 Adam David George
Secretary
97,008   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Adam David George
Secretary
3,636   Derivative/Non-derivative trans. at $0 per share. 0
01/04/2021 Cabot Brown
Director
1,440   Derivative/Non-derivative trans. at $9.62 per share. 13,852
01/04/2021 Catherine J. Mackey
Director
1,440   Derivative/Non-derivative trans. at $9.62 per share. 13,852
01/04/2021 Alicia Secor
Director
1,440   Derivative/Non-derivative trans. at $9.62 per share. 13,852
01/04/2021 Cabot Brown
Director
3,576   Derivative/Non-derivative trans. at $0 per share. 0
01/04/2021 Catherine J. Mackey
Director
3,576   Derivative/Non-derivative trans. at $0 per share. 0
01/04/2021 Alicia Secor
Director
3,576   Derivative/Non-derivative trans. at $0 per share. 0
12/31/2020 Justin D. Gover
Chief Executive Officer; Director
456,048   Gift at $0 per share. 0
12/31/2020 Justin D. Gover
Chief Executive Officer; Director
456,048   Gift at $0 per share. 0
12/08/2020 Geoffrey William Guy
Executive Chairman; Director
167,064   Disposition at $10.76 per share. 1,797,608
12/08/2020 Geoffrey William Guy
Executive Chairman; Director
72,936   Disposition at $10.69 per share. 779,685
12/07/2020 Geoffrey William Guy
Executive Chairman; Director
10,920   Disposition at $11.44 per share. 124,924
12/07/2020 Geoffrey William Guy
Executive Chairman; Director
14,760   Disposition at $11.4 per share. 168,264
12/07/2020 Geoffrey William Guy
Executive Chairman; Director
13,260   Disposition at $11.28 per share. 149,572
12/07/2020 Geoffrey William Guy
Executive Chairman; Director
14,340   Disposition at $11.19 per share. 160,464
12/07/2020 Geoffrey William Guy
Executive Chairman; Director
69,156   Disposition at $11.13 per share. 769,706
12/07/2020 Geoffrey William Guy
Executive Chairman; Director
85,980   Disposition at $11.04 per share. 949,219
12/07/2020 Geoffrey William Guy
Executive Chairman; Director
136,656   Disposition at $10.97 per share. 1,499,116
12/07/2020 Geoffrey William Guy
Executive Chairman; Director
55,332   Disposition at $10.87 per share. 601,458
12/07/2020 Geoffrey William Guy
Executive Chairman; Director
79,596   Disposition at $10.8 per share. 859,636
12/07/2020 Douglas B. Snyder
Chief Legal Officer
2,400   Disposition at $11.3 per share. 27,120
12/07/2020 Douglas B. Snyder
Chief Legal Officer
1,200   Disposition at $11.19 per share. 13,428
12/07/2020 Douglas B. Snyder
Chief Legal Officer
5,076   Disposition at $11.11 per share. 56,394
12/07/2020 Douglas B. Snyder
Chief Legal Officer
3,984   Disposition at $11.02 per share. 43,903
12/07/2020 Douglas B. Snyder
Chief Legal Officer
9,444   Disposition at $10.95 per share. 103,411
12/07/2020 Douglas B. Snyder
Chief Legal Officer
4,800   Disposition at $10.84 per share. 52,032
12/01/2020 Christopher John Tovey
Chief Operating Officer
9,060   Disposition at $11.79 per share. 106,817
12/01/2020 Christopher John Tovey
Chief Operating Officer
19,500   Disposition at $11.74 per share. 228,930
12/01/2020 Christopher John Tovey
Chief Operating Officer
28,560   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/gwph

MarketWatch News on GWPH

  1. Medical cannabis company Kanabo soars in London market debut

    3:28 p.m. Feb. 16, 2021

    - Lina Saigol

  2. Pot Stocks Are Flying High. Here Are 4 on Firm Footing.

    3:14 p.m. Feb. 13, 2021

    - Barron's Online

  3. Watch the warnings coming from the stock market’s sell signals

    10:47 a.m. Feb. 4, 2021

    - Lawrence G. McMillan

  4. Jazz Pharmaceuticals expects deal to drive double-digit revenue growth in first full year

    7:33 a.m. Feb. 3, 2021

    - Ciara Linnane

  5. GW Pharma shares halted premarket for the news

    7:34 a.m. Feb. 3, 2021

    - Ciara Linnane

  6. Jazz Pharmaceuticals expects deal to boost earnings in first full year after close

    7:33 a.m. Feb. 3, 2021

    - Ciara Linnane

  7. Jazz Pharmaceuticals to acquire GW Pharma for $7.2 bln in cash and stock

    7:32 a.m. Feb. 3, 2021

    - Ciara Linnane

  8. Jazz Pharmaceuticals expects deal to close in Q2

    7:32 a.m. Feb. 3, 2021

    - Ciara Linnane

  9. GW Pharmaceuticals sees Q4 sales $148 mln; FactSet consensus $141.2 mln

    7:04 a.m. Jan. 11, 2021

    - Tomi Kilgore

  10. Pot stocks pop ahead of U.S., UN votes on cannabis legalization

    3:33 p.m. Nov. 30, 2020

    - Jeremy C. Owens

  11. Loading more headlines...
/news/nonmarketwatch/company/us/gwph

Other News on GWPH

  1. Recreational marijuana legalization is coming to Virginia

    2:24 a.m. March 1, 2021

    - Seeking Alpha

  2. GW Pharma get European nod on expanded label for Epidyolex

    11:09 a.m. Feb. 26, 2021

    - Seeking Alpha

  3. Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull

    7:52 a.m. Feb. 24, 2021

    - Zacks.com

  4. 8 Medical Marijuana Stocks That Are Just What the Doctor Ordered

    11:46 a.m. Feb. 23, 2021

    - InvestorPlace.com

  5. Should You Invest in Marijuana Stocks & ETFs Now?

    4:29 p.m. Feb. 18, 2021

    - Zacks.com

  6. Loading more headlines...

At a Glance

GW Pharmaceuticals Plc

Sovereign House

Vision Park, Chivers Way

Histon

Cambridge, Cambridgeshire CB24 9BZ

Phone

441223266800

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$531.31M

Net Income

$-58.58M

2020 Sales Growth

70.0%

Employees

-

/news/pressrelease/company/us/gwph

Press Releases on GWPH

  1. Hot Penny Stocks to Watch Today If You Like Marijuana Stocks

    4:10 p.m. Feb. 24, 2021

    - Penny Stocks

  2. Should Investors Be Watching These Top Biotech Stocks This Month?

    4:08 p.m. Feb. 24, 2021

    - StockMarket.com

  3. This is Why Cannabis Stocks Could Reach New Highs in 2021

    8:30 a.m. Feb. 4, 2021

    - Baystreet.ca

  4. SHAREHOLDER ALERT: WeissLaw LLP Investigates GW Pharmaceuticals plc

    4:46 p.m. Feb. 3, 2021

    - PR Newswire - PRF

  5. Loading more headlines...
Link to MarketWatch's Slice.